Bosh sahifaB1ME34 • BVMF
add
Beigene Ltd Bdr
Yopilish kursi
53,87 R$
Yillik diapazon
41,50 R$ - 66,48 R$
Bozor kapitalizatsiyasi
235,20 mlrd HKD
Oʻrtacha hajm
121,00
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,19 mlrd | 84,84% |
Joriy xarajat | 1,09 mlrd | 19,51% |
Sof foyda | -139,70 mln | 58,27% |
Sof foyda marjasi | -11,75 | 77,43% |
Har bir ulushga tushum | -1,43 | -429,63% |
EBITDA | -33,25 mln | 90,73% |
Amaldagi soliq stavkasi | -112,84% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 2,63 mlrd | -17,16% |
Jami aktivlari | 5,92 mlrd | 1,99% |
Jami passivlari | 2,59 mlrd | 14,14% |
Umumiy kapital | 3,33 mlrd | — |
Tarqatilgan aksiyalar | 106,72 mln | — |
Narxi/balansdagi bahosi | 1,73 | — |
Aktivlardan daromad | -3,26% | — |
Kapitaldan daromad | -4,29% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -139,70 mln | 58,27% |
Operatsiyalardan naqd pul | 111,61 mln | 128,21% |
Sarmoyadan naqd pul | -247,31 mln | 26,86% |
Moliyadan naqd pul | 30,05 mln | -92,11% |
Naqd pulning sof oʻzgarishi | -155,64 mln | 57,59% |
Boʻsh pul | 434,97 mln | 505,95% |
Haqida
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Tashkil etilgan
28-okt, 2010
Sayt
Xodimlar soni
11 000
